These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35945246)

  • 61. Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
    Cerro-Herreros E; Chakraborty M; Pérez-Alonso M; Artero R; Llamusí B
    Sci Rep; 2017 Jun; 7(1):2843. PubMed ID: 28588248
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improvement of the diagnostic procedure in proximal myotonic myopathy/myotonic dystrophy type 2.
    Jakubiczka S; Vielhaber S; Kress W; Küpferling P; Reuner U; Kunath B; Wieacker P
    Neurogenetics; 2004 Feb; 5(1):55-9. PubMed ID: 14666402
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
    Meola G; Cardani R
    Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dysautonomia as Onset Symptom of Myotonic Dystrophy Type 2.
    Rossi S; Romano A; Modoni A; Perna F; Rizzo V; Santoro M; Monforte M; Pieroni M; Luigetti M; Pomponi MG; Silvestri G
    Eur Neurol; 2018; 79(3-4):166-170. PubMed ID: 29533949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
    Meola G; Cardani R
    Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
    Timchenko L
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
    [TBL] [Abstract][Full Text] [Related]  

  • 67. DM2 CCTG*CAGG repeats are crossover hotspots that are more prone to expansions than the DM1 CTG*CAG repeats in Escherichia coli.
    Dere R; Wells RD
    J Mol Biol; 2006 Jun; 360(1):21-36. PubMed ID: 16753177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A fly model for the CCUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1.
    Yu Z; Goodman LD; Shieh SY; Min M; Teng X; Zhu Y; Bonini NM
    Hum Mol Genet; 2015 Feb; 24(4):954-62. PubMed ID: 25305073
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular and clinical characteristics of myotonic dystrophy type 1 in koreans.
    Kim SY; Kim JY; Kim GP; Sung JJ; Lim KS; Lee KW; Chae JH; Hong YH; Seong MW; Park SS
    Korean J Lab Med; 2008 Dec; 28(6):483-92. PubMed ID: 19127114
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single-Tube Dodecaplex PCR Panel of Polymorphic Microsatellite Markers Closely Linked to the
    Lian M; Zhao M; Lee CG; Chong SS
    Clin Chem; 2017 Jun; 63(6):1127-1140. PubMed ID: 28428361
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
    Schneider-Gold C; Timchenko LT
    Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modeling Myotonic Dystrophy Type 2 Using
    Marzullo M; Coni S; De Simone A; Canettieri G; Ciapponi L
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762484
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of interrupting residues on DNA dumbbell structures formed by CCTG tetranucleotide repeats associated with myotonic dystrophy type 2.
    Yang Y; Wang Y; Yan Z; Li Z; Guo P
    FEBS Lett; 2024 Jun; ():. PubMed ID: 38922834
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Massive contractions of Myotonic Dystrophy Type 2-associated CCTG tetranucleotide repeats occur via double strand break repair with distinct requirements for helicases.
    Papp D; Hernandez LA; Mai TA; Haanen TJ; O'Donnell MA; Duran AT; Hernandez SM; Narvanto JE; Arguello B; Onwukwe MO; Kolar K; Mirkin SM; Kim JC
    bioRxiv; 2023 Jul; ():. PubMed ID: 37461657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myotonic dystrophy types 1 and 2.
    Ashizawa T; Sarkar PS
    Handb Clin Neurol; 2011; 101():193-237. PubMed ID: 21496635
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Molecular pathways to myotonic dystrophy].
    Ishiura S
    Nihon Rinsho; 2005 Mar; 63(3):515-21. PubMed ID: 15773354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phenotype and management of neurologic intronic repeat disorders (NIRDs).
    Finsterer J
    Rev Neurol (Paris); 2023 Mar; 179(3):173-182. PubMed ID: 36371266
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathogenic RNA repeats: an expanding role in genetic disease.
    Ranum LP; Day JW
    Trends Genet; 2004 Oct; 20(10):506-12. PubMed ID: 15363905
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection and discovery of repeat expansions in ataxia enabled by next-generation sequencing: present and future.
    Rafehi H; Bennett MF; Bahlo M
    Emerg Top Life Sci; 2023 Dec; 7(3):349-359. PubMed ID: 37733280
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis.
    Butterfield RJ; Imburgia C; Mayne K; Newcomb T; Dunn DM; Duval B; Feldkamp ML; Johnson NE; Weiss RB
    Mol Genet Genomic Med; 2021 Apr; 9(4):e1619. PubMed ID: 33624941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.